fluconazole has been researched along with sertraline in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.88) | 29.6817 |
| 2010's | 12 (70.59) | 24.3611 |
| 2020's | 4 (23.53) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ji, C; Li, J; Li, W; Liu, N; Sheng, C; Tu, J; Yang, W; Yun, Z | 1 |
| Atkinson, AC; Bogacka, B; Johnson, PJ; Patan, M; Youdim, KA | 1 |
| Lin, X; Sachs, MS; Wang, L; Wu, C; Zhai, B | 1 |
| Abassi, M; Boulware, DR; Lofgren, S; Rhein, J | 1 |
| Campos, RS; Cavalcanti, BC; Costa Silva, RA; da Cruz Fonseca, SG; da Silva Gaspar, B; da Silva, AR; da Silva, CR; de Andrade Neto, JB; de Lucena, DF; de Moraes, MO; do Nascimento, FBSA; Gaspar, DM; Grangeiro, TB; Josino, MAA; Nobre Júnior, HV; Sampaio, LS | 1 |
| Boulware, DR; Meya, DB; Rajasingham, R | 1 |
| Abassi, M; Alhadab, AA; Boulware, DR; Brundage, RC; Meya, DB; Musubire, A; Nicol, MR; Rhein, J; Tugume, L; Williams, DA | 1 |
| Bangdiwala, AS; Boulware, DR; Hullsiek, KH; Kirumira, P; Meya, DB; Nalintya, E; Naluyima, R; Namanda, S; Nikweri, Y; Rajasingham, R; Rutakingirwa, MK; Skipper, CP; Turya, F | 1 |
| abuRokba, W; Alkhalifa, BA; Bulatova, NR; Darwish, RM | 1 |
| Day, JN; Flower, B; Ngan, NTT | 1 |
3 review(s) available for fluconazole and sertraline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Recent advances in AIDS-related cryptococcal meningitis treatment with an emphasis on resource limited settings.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Anti-HIV Agents; Antifungal Agents; Antigens, Fungal; Asymptomatic Diseases; Cost-Benefit Analysis; Cryptococcus neoformans; Developing Countries; Drug Administration Schedule; Fluconazole; Humans; Mass Screening; Meningitis, Cryptococcal; Sertraline | 2017 |
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?
Topics: Adult; Amphotericin B; Antifungal Agents; Fluconazole; Flucytosine; Glucocorticoids; HIV Infections; Humans; Meningitis, Cryptococcal; Sertraline; Tamoxifen | 2022 |
1 trial(s) available for fluconazole and sertraline
| Article | Year |
|---|---|
Adjunctive sertraline for asymptomatic cryptococcal antigenemia: A randomized clinical trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Antigens, Fungal; Asymptomatic Infections; Cryptococcosis; Cryptococcus; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluconazole; Humans; Male; Meningitis, Cryptococcal; Serotonin Syndrome; Sertraline | 2020 |
13 other study(ies) available for fluconazole and sertraline
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Discovery of Novel Sertraline Derivatives as Potent Anti-
Topics: Antidepressive Agents; Antifungal Agents; Cryptococcus; Cryptococcus neoformans; Humans; Meningitis, Cryptococcal; Microbial Sensitivity Tests; Sertraline | 2022 |
Potential application of D-optimal designs in the efficient investigation of cytochrome P450 inhibition kinetic models.
Topics: Aryl Hydrocarbon Hydroxylases; Binding, Competitive; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6 Inhibitors; Fluconazole; Humans; In Vitro Techniques; Kinetics; Microsomes, Liver; Nonlinear Dynamics; Research Design; Sertraline | 2010 |
The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections.
Topics: Animals; Antidepressive Agents; Cryptococcosis; Cryptococcus neoformans; Female; Fluconazole; Mice; Microbial Sensitivity Tests; Saccharomyces cerevisiae; Sertraline | 2012 |
In vitro anti-Candida activity of selective serotonin reuptake inhibitors against fluconazole-resistant strains and their activity against biofilm-forming isolates.
Topics: Animals; Antifungal Agents; Apoptosis; Biofilms; Candida; Cell Count; Cell Death; Cell Line; Cell Proliferation; DNA Damage; DNA, Fungal; Drug Resistance, Fungal; Fibroblasts; Flow Cytometry; Fluconazole; In Vitro Techniques; Membrane Potentials; Mice; Microbial Sensitivity Tests; Microbial Viability; Mitochondrial Membranes; Paroxetine; Plasma; Selective Serotonin Reuptake Inhibitors; Sertraline | 2017 |
Are fluconazole or sertraline dose adjustments necessary with concomitant rifampin?
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antibiotics, Antitubercular; Antifungal Agents; Dose-Response Relationship, Drug; Drug Interactions; Fluconazole; HIV Infections; Humans; Mycoses; Rifampin; Sertraline; Tuberculosis | 2018 |
Pharmacokinetics-pharmacodynamics of sertraline as an antifungal in HIV-infected Ugandans with cryptococcal meningitis.
Topics: Adult; Amphotericin B; Antifungal Agents; Brain; Cerebrospinal Fluid; Female; Fluconazole; HIV Infections; Humans; Male; Meningitis, Cryptococcal; Pilot Projects; Sertraline; Uganda | 2019 |
Serotonin reuptake inhibitors effect on fluconazole activity against resistant Candida glabrata strains.
Topics: Antifungal Agents; Candida glabrata; Drug Resistance, Fungal; Fluconazole; Microbial Sensitivity Tests; Selective Serotonin Reuptake Inhibitors; Sertraline | 2022 |